Results 251 to 260 of about 84,919 (278)
Some of the next articles are maybe not open access.
Journal of the American Academy of Nurse Practitioners, 1996
Return of angina within 6 months of a catheter-based treatment of coronary artery disease usually reflects restenosis due to an overly aggressive local healing response to the procedure-related arterial injury. The restenotic lesion should be treated aggressively.
C, Brown +5 more
openaire +2 more sources
Return of angina within 6 months of a catheter-based treatment of coronary artery disease usually reflects restenosis due to an overly aggressive local healing response to the procedure-related arterial injury. The restenotic lesion should be treated aggressively.
C, Brown +5 more
openaire +2 more sources
Costs of coronary restenosis (Lovastatin Restenosis Trial)
The American Journal of Cardiology, 1996Within the Lovastatin Restenosis Trial, restenosis has been clearly shown to increase resource utilization and costs. While it is not possible to generalize these results to other patient populations, it is clear that successful efforts to decrease restenosis will certainly improve efficacy while decreasing follow-up costs and increasing the cost ...
S P, Gilbert +3 more
openaire +2 more sources
Interventional Cardiology Clinics, 2022
In-stent restenosis (ISR) remains a potential complication after percutaneous coronary intervention, even in the era of drug-eluting stents, and its treatment remains suboptimal. Neoatherosclerosis is an important component of the pathology of ISR and is accelerated in drug-eluting stents compared with bare-metal stents.
Kenji, Kawai +2 more
openaire +2 more sources
In-stent restenosis (ISR) remains a potential complication after percutaneous coronary intervention, even in the era of drug-eluting stents, and its treatment remains suboptimal. Neoatherosclerosis is an important component of the pathology of ISR and is accelerated in drug-eluting stents compared with bare-metal stents.
Kenji, Kawai +2 more
openaire +2 more sources
Current Treatment Options in Cardiovascular Medicine, 2001
Angiographic restenosis occurs in 30% to 50% of patients after percutaneous transluminal coronary angioplasty (PTCA) with 20% to 30% target vessel revascularization at one year, and is associated with increased morbidity, mortality and health care costs. Intracoronary stents are the first line of therapy against restenosis after angioplasty.
Mehran, Moussavian +2 more
openaire +2 more sources
Angiographic restenosis occurs in 30% to 50% of patients after percutaneous transluminal coronary angioplasty (PTCA) with 20% to 30% target vessel revascularization at one year, and is associated with increased morbidity, mortality and health care costs. Intracoronary stents are the first line of therapy against restenosis after angioplasty.
Mehran, Moussavian +2 more
openaire +2 more sources
Interventional Cardiology Clinics, 2016
In-stent restenosis (ISR) is the narrowing of a stented coronary artery lesion. The mean time from percutaneous coronary intervention (PCI) to ISR was 12 months with drug-eluting stents (DES) and 6 months with bare metal stents (BMS). ISR typically presents as recurrent angina. The use of DES has significantly reduced the rate of ISR compared with BMS.
Michael S, Lee, Gaurav, Banka
openaire +2 more sources
In-stent restenosis (ISR) is the narrowing of a stented coronary artery lesion. The mean time from percutaneous coronary intervention (PCI) to ISR was 12 months with drug-eluting stents (DES) and 6 months with bare metal stents (BMS). ISR typically presents as recurrent angina. The use of DES has significantly reduced the rate of ISR compared with BMS.
Michael S, Lee, Gaurav, Banka
openaire +2 more sources
Archives of Surgery, 1985
To the Editor.—We would like to thank Dr Thompson for his comments on our recent article.1We agree that our follow-up was short; however, a recent update of our results indicates a cumulative stroke-free survival of 97% at three years, with 65 patients having been followed up prospectively for this time period.
M P, Colgan, V, Kingston, G, Shanik
openaire +2 more sources
To the Editor.—We would like to thank Dr Thompson for his comments on our recent article.1We agree that our follow-up was short; however, a recent update of our results indicates a cumulative stroke-free survival of 97% at three years, with 65 patients having been followed up prospectively for this time period.
M P, Colgan, V, Kingston, G, Shanik
openaire +2 more sources
Surgical Clinics of North America, 1998
The multitude of actions and interacting components involved in inciting and sustaining myointimal hyperplasia and restenosis effectively precludes the use of a single type of intervention. No pharmacologic approach has been conclusively shown to prevent coronary restenosis after balloon angioplasty or graft restenosis after peripheral arterial bypass.
S A, Kagan, S I, Myers
openaire +2 more sources
The multitude of actions and interacting components involved in inciting and sustaining myointimal hyperplasia and restenosis effectively precludes the use of a single type of intervention. No pharmacologic approach has been conclusively shown to prevent coronary restenosis after balloon angioplasty or graft restenosis after peripheral arterial bypass.
S A, Kagan, S I, Myers
openaire +2 more sources
Hyperhomocysteinemia and Restenosis
European Journal of Cardiovascular Prevention & Rehabilitation, 2001This study was undertaken to assess the effect of plasma homocysteine level on angiographic restenosis 6 months after coronary angioplasty.The plasma homocysteine level was measured in 100 consecutive patients at the time of coronary angioplasty, 56 patients who attended a 6-month follow-up angiogram being enrolled to the study; the 44 patients without
S D, Kumbasar +9 more
openaire +2 more sources
New England Journal of Medicine, 2002
Over the past two decades, percutaneous coronary intervention has revolutionized the treatment of symptomatic coronary artery disease, sparing countless patients the need for surgical revascularization. This year, up to a million procedures are likely to be performed in North America alone. The success of percutaneous coronary intervention has been due
openaire +2 more sources
Over the past two decades, percutaneous coronary intervention has revolutionized the treatment of symptomatic coronary artery disease, sparing countless patients the need for surgical revascularization. This year, up to a million procedures are likely to be performed in North America alone. The success of percutaneous coronary intervention has been due
openaire +2 more sources
Restenosis: Intracoronary brachytherapy
Current Treatment Options in Cardiovascular Medicine, 2002Though interventional strategies have revolutionized the management of patients with symptomatic coronary artery disease, in-stent restenosis has emerged as the single most important limitation of long-term success following percutaneous coronary intervention.
Douglas E., Drachman, Daniel I., Simon
openaire +2 more sources